AstraZeneca
overall safety profile a discontinuation | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2022
Slide
17 of 35
Related slides by other companies
ATAI
Investor Presentation
February 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Alkermes
Results
October 2023
significantly improved sleep latency with a clear dose response | Alkermes
Adagio Therapeutics
Investor Presentation
May 2023
ongoing phase trial of with initial data planned for | Adagio Therapeutics
ATAI
Investor Presentation
January 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io